Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 19Neoplasms 7Breast Neoplasms 5Pancreatic Neoplasms 4Hematologic Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Prostatic Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Gastrointestinal Neoplasms 2Erdheim-Chester Disease 2Colorectal Neoplasms 2Xanthogranuloma, Juvenile 1Thyroid Neoplasms 1Thrombocytosis 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Clear Cell 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

atezolizumab 2irinotecan sucrosofate 1cobimetinib 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Immunoglobulin G 1Fluorouracil 1Famotidine 1Disulfides 1Diphenhydramine 1Dexamethasone 1DNA Fingerprinting 1Chemoradiotherapy 1Calcium Dobesilate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Mucinous × cobimetinib × Clear all
NCT03108131 2025-05-28

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

M.D. Anderson Cancer Center

Phase 2 Completed
49 enrolled 10 charts

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡